Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 35.65
(3.78%)
TWD 35.65
(3.78%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 705.32 Million TWD | -9.63% |
| 2022 | 780.44 Million TWD | 21.87% |
| 2021 | 640.39 Million TWD | -11.85% |
| 2020 | 726.45 Million TWD | 33.81% |
| 2019 | 542.9 Million TWD | 44.5% |
| 2018 | 375.71 Million TWD | 0.02% |
| 2017 | 375.64 Million TWD | 7.44% |
| 2016 | 349.61 Million TWD | 2.56% |
| 2015 | 340.89 Million TWD | 16.84% |
| 2014 | 291.75 Million TWD | 23.21% |
| 2013 | 236.8 Million TWD | 18.43% |
| 2012 | 199.94 Million TWD | 9.38% |
| 2011 | 182.79 Million TWD | 38.21% |
| 2010 | 132.26 Million TWD | 1.24% |
| 2009 | 130.63 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 697 Million TWD | -1.18% |
| 2024 Q2 | 741.89 Million TWD | 6.44% |
| 2023 Q4 | 705.32 Million TWD | -7.04% |
| 2023 Q1 | 816.45 Million TWD | 4.61% |
| 2023 FY | 705.32 Million TWD | -9.63% |
| 2023 Q2 | 801.66 Million TWD | -1.81% |
| 2023 Q3 | 758.7 Million TWD | -5.36% |
| 2022 Q3 | 763.32 Million TWD | -0.65% |
| 2022 FY | 780.44 Million TWD | 21.87% |
| 2022 Q4 | 780.44 Million TWD | 2.24% |
| 2022 Q2 | 768.32 Million TWD | 11.37% |
| 2022 Q1 | 689.88 Million TWD | 7.73% |
| 2021 Q2 | 632.04 Million TWD | -5.81% |
| 2021 Q3 | 611.39 Million TWD | -3.27% |
| 2021 FY | 640.39 Million TWD | -11.85% |
| 2021 Q4 | 640.39 Million TWD | 4.74% |
| 2021 Q1 | 671.05 Million TWD | -7.63% |
| 2020 Q4 | 726.45 Million TWD | 17.45% |
| 2020 Q2 | 667.24 Million TWD | 10.7% |
| 2020 FY | 726.45 Million TWD | 33.81% |
| 2020 Q3 | 618.51 Million TWD | -7.3% |
| 2020 Q1 | 602.75 Million TWD | 11.02% |
| 2019 Q1 | 434.72 Million TWD | 15.7% |
| 2019 Q4 | 542.9 Million TWD | 21.9% |
| 2019 FY | 542.9 Million TWD | 44.5% |
| 2019 Q3 | 445.36 Million TWD | 0.68% |
| 2019 Q2 | 442.35 Million TWD | 1.76% |
| 2018 Q2 | 393.56 Million TWD | 1.29% |
| 2018 Q3 | 411.07 Million TWD | 4.45% |
| 2018 FY | 375.71 Million TWD | 0.02% |
| 2018 Q1 | 388.57 Million TWD | 3.44% |
| 2018 Q4 | 375.71 Million TWD | -8.6% |
| 2017 Q3 | 398.52 Million TWD | 4.7% |
| 2017 Q4 | 375.64 Million TWD | -5.74% |
| 2017 FY | 375.64 Million TWD | 7.44% |
| 2017 Q1 | 352.77 Million TWD | 0.9% |
| 2017 Q2 | 380.61 Million TWD | 7.89% |
| 2016 Q4 | 349.61 Million TWD | 5.91% |
| 2016 FY | 349.61 Million TWD | 2.56% |
| 2016 Q3 | 330.1 Million TWD | 11.85% |
| 2016 Q2 | 295.14 Million TWD | -2.93% |
| 2016 Q1 | 304.06 Million TWD | -10.8% |
| 2015 Q3 | 337.13 Million TWD | 14.67% |
| 2015 Q4 | 340.89 Million TWD | 1.11% |
| 2015 FY | 340.89 Million TWD | 16.84% |
| 2015 Q1 | 272.19 Million TWD | -6.71% |
| 2015 Q2 | 294 Million TWD | 8.01% |
| 2014 Q2 | 255.89 Million TWD | 9.9% |
| 2014 Q1 | 232.83 Million TWD | -1.67% |
| 2014 Q4 | 291.75 Million TWD | 21.18% |
| 2014 Q3 | 240.77 Million TWD | -5.91% |
| 2014 FY | 291.75 Million TWD | 23.21% |
| 2013 Q4 | 236.8 Million TWD | -6.42% |
| 2013 Q1 | 208.56 Million TWD | 4.31% |
| 2013 Q2 | 233.46 Million TWD | 11.94% |
| 2013 Q3 | 253.05 Million TWD | 8.39% |
| 2013 FY | 236.8 Million TWD | 18.43% |
| 2012 FY | 199.94 Million TWD | 9.38% |
| 2012 Q1 | 169.27 Million TWD | -7.4% |
| 2012 Q4 | 199.94 Million TWD | 6.26% |
| 2012 Q3 | 188.16 Million TWD | 12.94% |
| 2012 Q2 | 166.61 Million TWD | -1.57% |
| 2011 Q3 | 184.46 Million TWD | 30.53% |
| 2011 FY | 182.79 Million TWD | 38.21% |
| 2011 Q1 | 154.86 Million TWD | 17.09% |
| 2011 Q2 | 141.31 Million TWD | -8.75% |
| 2011 Q4 | 182.79 Million TWD | -0.9% |
| 2010 Q4 | 132.26 Million TWD | 0.0% |
| 2010 FY | 132.26 Million TWD | 1.24% |
| 2009 FY | 130.63 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Maxigen Biotech Inc. | 85.18 Million TWD | -727.987% |
| SciVision Biotech Inc. | 87.25 Million TWD | -708.372% |
| Bionime Corporation | 491.25 Million TWD | -43.574% |
| Pegavision Corporation | 583.47 Million TWD | -20.882% |
| Visco Vision Inc. | 606.06 Million TWD | -16.377% |